Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 105

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 105
---

Audit Committee chairperson are communicated to the full Audit Committee at its next regular meeting and the Audit Committee reviews
services and fees for the fiscal year at each such meeting. Pursuant to these procedures, the Audit Committee approved the foregoing
services provided by Cherry Bekaert LLP and Salberg & Company P.A.

85

PART
IV

Item
15. Exhibits, Financial Statement Schedules.

The
information called for by this Item is incorporated herein by reference to the Exhibit Index in this Form 10-K.

    Number
     
    Description

    3.1
     
    Third
    Amended and Restated Articles of Incorporation of MIRA Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to Form S-1
    filed July 28, 2023).
  
    3.2
     
    Amended
    and Restated Bylaws of MIRA Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.3 to Form S-1 filed July 28, 2023).
  
    4.1
     
    Common
    Stock Purchase Warrant, dated April 28, 2023, between MIRA Pharmaceuticals, Inc. and Bay Shore Trust (incorporated by reference to
    Exhibit 4.2 to Form S-1 filed July 28, 2023).
  
    4.2
     
    Common
    Stock Purchase Warrant from the Company to MIRALOGX, dated November 15, 2023 (incorporated by reference to Exhibit 10.2 to the Current
    Report on Form 8-K filed November 20, 2023).
  
    4.3
     
    Representative’s
    Warrant, dated August 7, 2023 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed August
    7, 2023).
  
    4.4*
     
    Description of Securities of the Registrant
  
    10.1+
     
    2022
    Omnibus Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to Form S-1 filed July 28, 2023).
  
    10.2+
     
    Form
    of Stock Option Award under 2022 Omnibus Incentive Plan (